The TPA controversy and the drug approval process. The view of the Cardiovascular and Renal Drugs Advisory Committee.
D002543:Cerebral Hemorrhage / Q000139:chemically induced; D006801:Humans; D008402:Mass Media; D009203:Myocardial Infarction / Q000188:drug therapy; D011367:Professional Staff Committees / Q000458:organization & administration*; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D013300:Streptokinase / Q000627:therapeutic use; D010959:Tissue Plasminogen Activator / Q000009:adverse effects / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration / Q000458:organization & administration*
D011994:Recombinant Proteins; D013300:Streptokinase; D010959:Tissue Plasminogen Activator